Gastrointestinal effects are among the most frequently reported adverse events with GLP-1 therapies and typically include nausea, vomiting, diarrhea, constipation, and abdominal pain
SOD: copper-zinc SOD (Cu/Zn SOD), mainly present in the Graafian follicle and manganese SOD (MnSOD) concentrated mainly in the corpus luteum (124)
Obesity and bone health: a complex link
Conversely, participants receiving GLP-1 RAs were consistently more likely to report experiencing gastrointestinal side effects
One study found that mice treated with 5-Amino-1MQ had significantly lower body weight, smaller fat cells, and less overall fat mass than untreated mice , despite no difference in food intake
TB-500 may exert an anti-apoptotic potential through multiple molecular pathways